[Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha]. / Switch étanercept--infliximab dans la polyarthrite rhumatoïde. 14 patients sur 132 traités par anti-TNFalpha.
Presse Med
; 31(39 Pt 1): 1836-9, 2002 Nov 23.
Article
en Fr
| MEDLINE
| ID: mdl-12496713
OBJECTIVE: Patients with severe rheumatoid arthritis and resistant to at least three DMARDS can benefit from anti-TNFalpha (tumor necrosis factor) therapy. In some patients, because of inefficacy or adverse events, treatment with one of the two available TNFalpha drugs (etanercept and infliximab) must be stopped. In this study, we explored the results in efficacy and tolerance of switching from one anti-TNFalpha to the other. PATIENTS: Between August 1999 and January 2002, we administered one of the two anti TNFalpha drugs to 131 patients: 67 patients received infiximab and 64 etanercept. RESULTS: Among the 67 patients treated with infliximab, 17 patients had to stop treatment. In 8 of them (4 allergies, 2 infections and 2 non responders) the switch from infliximab to etanercept was beneficial for 5 patients, 2 patients did not respond and 1 patient withdrew for personal reasons. Among the 64 patients treated with etanercept, 13 had to stop treatment. In 6 of them (2 adverse events, 4 failures) the switch from etanercept to infliximab was beneficial for 3 patients, 2 did not respond and 1 withdrew because of adverse events. CONCLUSION: In all, 14 patients with severe rheumatoid arthritis and treated by one of the two TNFalpha drugs (and in whom treatment was stopped because of adverse events or inefficacy) benefited from the switch to the other anti- TNFalpha, with excellent response in 8 out of 14 patients.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Artritis Reumatoide
/
Inmunoglobulina G
/
Receptores del Factor de Necrosis Tumoral
/
Antirreumáticos
/
Anticuerpos Monoclonales
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Fr
Revista:
Presse Med
Año:
2002
Tipo del documento:
Article
País de afiliación:
Francia
Pais de publicación:
Francia